Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada, a biopharmaceutical company, has completed patient enrollment in its Phase II clinical trial evaluating treatment of bronchiectasis patients with inhaled Alpha-1 Antitrypsin delivered by the investigational eFlow nebulizer system.
Subscribe to our email newsletter
A total of 21 patients with bronchiectasis were enrolled and randomized into this, double-blind, placebo controlled Phase II study. The purpose of the trial is to investigate safety and efficacy of inhaled Alpha-1 Antitrypsin (AAT) in this patient population.
David Tsur, CEO of Kamada, said: “We are very pleased with the progress of this study and look forward to its upcoming completion. We believe that Kamada’s AAT delivered by Pari’s eFlow has the potential to become a novel treatment for bronchiectasis.
“Kamada is committed to the development of inhaled AAT to treat bronchiectasis and to proceed with its ongoing clinical efforts in AAT deficiency and cystic fibrosis.”